Financing Drugs in South-East Asia - Report of the First Meeting of the WHO/SEARO Working Group on Drug Financing, Korat, Thailand, 26-28 November 1996 - Health Economics and Drugs Series No. 004: 5. Country priorities for drug financing: 5.3 Nepal

Financing Drugs in South-East Asia - Report of the First Meeting of the WHO/SEARO Working Group on Drug Financing, Korat, Thailand, 26-28 November 1996 - Health Economics and Drugs Series No. 004
(1997; 72 pages)

Table of Contents

	Executive summary
		Background
		Drug financing issues
		Cost-sharing for drugs
		Monitoring for equity and quality
		Conclusions and recommendations
		Workshop evaluation
	1. Introduction
		1.1 Opening session
		1.2 Background
		1.3 Objectives of the Working Group
	2. Country presentations on drug financing
		2.1 Indonesia (presented by Dra Andayaningsih)
		2.2 Myanmar (presented by Dr Than Zaw)
		2.3 Nepal (presented by Dr Singh Karki)
		2.4 Thailand (presented by Dr Porntep Siriwanarangsun)
		2.5 Summary
	3. Korat provincial field visit
		3.1 Soongnern Community Hospital
		3.2 Maa Kleur Kao Health Centre
		3.3 Village drug funds (or drug cooperatives)
	4. Drug financing issues
		4.1 Drug financing alternatives (by Dr German Velasquez)
		4.2 Cost-sharing for drugs (by Dr Petcharat Pongcharoensuk)
		4.3 Monitoring for equity and quality (by Dr Jonathan Quick)
	5. Country priorities for drug financing
		5.1 Indonesia
		5.2 Myanmar
		5.3 Nepal
		5.4 Thailand
	6. Priorities for work group action
		6.1 Group A
		6.2 Group B
	7. Conclusions and recommendations
		7.1 Country priorities for action
		7.2 Recommendations
	Annex A. Agenda
	Annex B. List of participants
	Annex C. List of documents
	Annex D. Message from Regional Director, WHO South-East Asia Region
	Annex E. Evaluation of the meeting. Priorities for the Working Group
		1. Evaluation of the meeting
		2. Priorities for the next Working Group meeting

5.3 Nepal

1. Lack of coordinated effort among all NGOs, INGOs and public sector activities in drug financing.

2. Lack of proper guidelines and policies for the cost-sharing scheme.

3. Problem of purchasing quality drugs at the lowest prices.